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Abstract 
Although electrophiles are considered as detrimental to cells, accumulating recent evidence  
indicates that proliferating non-cancerous and particularly cancerous cells utilize these 
agents for pro-survival and cell cycle promoting signaling. Hence, the redox shift to mild 
oxidant release must be balanced by multiple defense mechanisms. Our latest findings 
demonstrate that cell cycle progression, which dictates oxidant level in stress-free conditions, 
determines PARP1 transcription. Growth modulating factors regulate CDK4/6-RBs-E2Fs 
2 
 
axis. In cells arrested in G1 and G0, RB1-E2F1 and RBL2-E2F4 dimers recruit chromatin 
remodelers such as HDAC1, SWI/SNF and PRC2 to condense chromatin and turn off 
transcription. Release of retinoblastoma-based repressive complexes from E2F-dependent 
gene promoters in response to cell transition to S phase enables transcription of PARP1. 
This enzyme contributes to repair of oxidative DNA damage by supporting several strand 
break repair pathways and nucleotide or base excision repair pathways, as well as acting as 
a co-activator of transcription factors such as NRF2 and HIF1a, which control expression of 
antioxidant enzymes involved in removal of electrophiles and secondary metabolites. 
Furthermore, PARP1 is indispensible for transcription of the pro-survival kinases MAP2K6, 
ERK1/2 and AKT1, and for maintaining MAPK activity by suppressing transcription of the 
MAPK inhibitor, MPK1. In summary, cell cycle controlled PARP1 transcription helps cells to 
adapt to a pro-oxidant redox shift. 
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1. Pro-oxidant physiology of proliferating cells 
Human cells proliferate in a variety of contexts. Controlled cell divisions play a particular 
function for development of the embryo, while in the adult organism mainly stem and some 
immune cells retain the ability to proliferate. Cancer cells, as a special type of transformed 
cells, are capable of unlimited and uncontrolled growth. Regardless of the type of dividing 
cell, proliferation imposes a requirement for energy and reducing power. Although 
mitochondrial oxidative phosphorylation is the most efficient source of ATP, it can cause 
extensive release of O2
•-, which is dismutated to H2O2 either in mitochondria (by SOD2) or in 
the cytoplasm (by SOD1). Therefore, above some critical threshold value of this oxidant in 
cell compartments, aerobic glycolysis becomes more favorable than oxidative 
phosphorylation in order to limit the hazardous waste products resulting from the 
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mitochondrial metabolic pathway [1]. During fatty acid oxidation, O2
•- and H2O2 can also be 
produced by xanthine oxidase in peroxisomes, which duplicate and are segregated between 
progeny cells. Although metabolically unrelated, NADPH oxidases act as a primary source of 
oxidants in macrophages and some cancer cells [2].  
Depending on the cell type, proliferation-inducing agents such as growth factors (platelet-
derived, fibroblast, epidermal, insulin-like and transforming growth factor β), cytokines (type I 
interferons, granulocyte-macrophage colony-stimulating factor), mutant K-ras or small 
GTPase Rac-1 elevate intracellular O2
•- through NADPH oxidase and/or mitochondria [3, 4]. 
Due to pressure induced by an elevated and sustained redox shift to a mild oxidative 
environment, cells have developed efficient mechanisms of adaptation and functional 
transformation of „bad” to „good” molecules, which promote cell proliferation and survival at 
different signaling levels [5].  
2. Cell cycle progression regulates PARP1 transcription 
Poly-ADP-ribose polymerase 1 (PARP1) is a multitasking enzyme that regulates many 
intracellular processes, including DNA repair, metabolism, signaling and transcription, by 
direct interaction with other proteins and DNA, involving their ADP-ribosylation and auto-
ADP-ribosylation of PARP1. The data acquired and published in the EMBL-EBI Expression 
Atlas indicate high PARP1 abundance in proliferating cancerous and non-cancerous cells 
(e.g. macrophages) [6]. In search for the link between PARP1 transcription and cell cycle 
progression, we recently revealed that cell arrest in G1 or exit to G0 lead to PARP1 
repression by retinoblastoma-based multiprotein complexes, which are also known to 
repress transcription of E2F-depndent genes encoding proteins responsible for cell transition 
to S phase [7]. The mode of growth inhibition determines the composition of the repressive 
complex at the PARP1 promoter, giving priority to E2F1-RB1 dimers under G1 arrest in 
cancer, as well as in CD34+ hematopoietic progenitor/stem cells treated with cycline-
dependent kinases 4 and 6 (CDK4/6) pharmacological inhibitors or depleted of nucleotides 
by mimosine. E2F4-RBL2-based complexes were found to be prevalent in differentiated cells 
(Figure 1). Since PARP1 is involved in cell protection against oxidants, one may think that 
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PARP1 repression in response to proliferation arrest may sensitize cells to agents that 
challenge redox homeostasis. Some ongoing and recruiting clinical trials have been testing 
FDA approved CDK4/6 inhibitors Palbociclib (IBRANCE®, PD0332991) and Ribociclib 
(LEE011, Kisqali) in combination with drugs such as doxorubicin, carboplatin and paclitaxel, 
which trigger acute redox imbalance [8].  
Furthermore, PARP1 enhances cell proliferation. Hormone-activated cyclin-dependent 
kinase 2 (CDK2) phosphorylates and activates PARP1, thereby facilitating H1 displacement 
and transcription of the majority of hormone-responsive genes in breast cancer [9]. In urinary 
bladder carcinoma cells, PARP1 regulates cyclin E expression, cell cycle re-entry and G1/S 
progression [10]. Thus, high levels of PARP1 in cancer cells promote cell cycle progression, 
which is associated with an increased level of oxidants, thereby maintaining PARP1 
transcription and creating a self-promoting cycle.  
3. PARP1 co-activates expression of proteins that enzymatically decompose oxidants 
and remove secondary metabolites 
The primary role in antioxidant defense and in cell adaptation to excessive oxidant or 
electrophile production is fulfilled by enzymatic antioxidant defense, which comprises direct 
scavengers of electrophiles, but also enzymes that detoxify the secondary metabolites. Many 
such enzymes are under transcriptional control of nuclear factor erythroid 2 (NFE2)-related 
factor 2 (NRF2), a basic leucine zipper (bZIP) protein, which dissociates from its repressor 
Keap1 and translocates to nucleus in response to a physiological shift in redox homeostasis 
towards oxidant production. NRF2 requires PARP1 for full transcriptional activity, because 
PARP1 facilitates interaction of NRF2 and NRF2-partner (small MAF protein; MAFG) with the 
antioxidant response element (ARE) (Figure 2) [11]. An inhibitory effect of PARP1 
knockdowns was found in breast cancer cells and proliferating mouse fibroblasts. Although in 
normal cells NRF2 suppresses tumor promotion and progression, this pathway is 
constitutively activated in various cancers by mutation and transcriptional repression of 
Keap-1, accumulation of Keap-1-NRF2 disruptors, transcriptional and post-translational 
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NRF2 induction. In view of NRF2 targets, this transcription factor provides chemoresistance 
and, like PARP1, has become a target for anticancer interventions [12].  
Another oxidant-counteracting mechanism that involves PARP1 is represented by its 
interaction with the transcription factor hypoxia-inducible factor 1-alpha (HIF1α), which 
undergoes activation during hypoxia and hypoxia-triggered redox imbalance [13, 14]. PARP1 
co-activates HIF1α-dependent transcription of genes, which promotes cell survival. In murine 
embryonic fibroblasts, PARP1 caused accumulation of HIF1α via upregulation of NO and 
oxidant production in cells treated with deferoxamine [15]. In addition to PARP1, HIF1α binds 
EP300/CBP acetylase(s) for full transcriptional activity. A similar observation was made for 
nuclear factor kappa B (NF-κB), activation of which required synergistic interaction with 
PARP1 and EP300/CBP. However, for HIF1α mutual dependence between these two types 
of co-activators has not been documented yet.  
Promoters of some antioxidant enzymes such as catalase, SOD1 or SOD2 carry the binding 
motif for NF-κB, but the role of PARP1 in transcription activation of these genes has not been 
confirmed. Instead, PARP1 level negatively correlates with mitochondrial SOD in cancer cells 
(EMBL-EBI Expression Atlas), where SOD2 overexpression causes a growth inhibitory effect 
by shifting the O2
•-/H2O2 balance towards H2O2 accumulation [16]. If PARP1 is involved in 
SOD2 repression, this enzyme could be capable of defining the intracellular repertoire of 
growth promoting or inhibiting oxidants. Furthermore, low SOD2 level is known to stabilize 
HIF1α [17]. 
4. PARP1 regulates redox-sensitive signaling pathways 
The roles that small species of oxidizing nature play in cellular signaling are becoming 
increasingly appreciated. Redox-sensitive pathways allow cells to adapt to mild 
oxidant/antioxidant imbalance and promote survival by linking redox shifts to post-
translational modifications of proteins and to their interactome [5, 18]. According to our and 
previous findings, PARP1 regulates transcription of numerous genes encoding redox sensors 
and mediators transmitting signals upstream or downstream of electrophile sources (Figure 
3). Redox-sensitive MAP kinase signaling serves as a good example of the PARP1-MAPK-
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ROS-cell survival axis since PARP1 couples transcription of MAP2K6, ERK1/2 and AKT1 
with the cell cycle progression, thereby assuring active transcription of kinases that have a 
pro-survival function under mild redox imbalance [19-26]. Furthermore, oxidative stress-
induced PARP1 activation represses transcription of MPK1, a known MAPK inhibitor [27]. 
Although in this particular case JNK and p38 were shown to act as pro-death kinases, the 
beneficial or detrimental activity of kinases and MAPK pathways is determined by the type of 
intracellular or extracellular stimuli that challenges redox homeostasis, for example whether 
the action is acute or prolonged, mild or severe, but is also dependent on the cell type. All 
these aspects also apply to PARP1. In addition to conditions listed above, PARP1-dependent 
cell life or death fate is determined by the pathway to which PARP1 contributes (pro-survival 
or suicidal), the direction (inhibition or stimulation) and mode of mutual interdependence with 
its interacting partner (direct protein-protein binding or covalent modification, i.e. ADP-
ribosylation). Oxidants are one of major agents triggering mono- or poly-ADP-ribosylation; 
the severity of oxidative stress determines the length of ADP polymer synthesized, thus also 
impinging on the beneficial or detrimental effect of PARP1 activation, since NAD+ is utilized 
as a substrate for ADP-ribosylation. High doses of H2O2 cause metabolic catastrophe, 
parthanatos, and activation of detrimental signaling pathways, while moderate PARylation 
protects cells from mild oxidative stress by attracting DNA repair complexes, clearing and 
removal of oxidized or damaged proteins, and re-establishing homeostasis [28, 29].  
5.  Cell cycle determines DNA repair mechanisms 
PARP1 actively contributes to numerous repair pathways of oxidative DNA lesions, which 
comprise covalent modifications of nucleobases as well as single and double strand breaks 
(SSB and DSB, respectively). The deformability of DNA within SSB is recognized by two 
flexibly linked N-terminal zinc fingers, and initiates self-assembly of remaining PARP1 
domains leading to activation of the C-terminal catalytic domain [30]. In case of DSB induced 
by oxidative stress, JNK 6 phosphorylates SIRT6. This enzyme is rapidly mobilized to break 
sites, where it potentiates recruitment and activation of PARP1, which in turn stimulates DSB 
repair [31]. In proliferating cells all repair mechanisms are active, and PARP1 is highly 
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expressed to support SSB repair (SSBR), base excision repair (BER), homologous 
recombination (HR), and alternative non-homologous end joining (Alt-NHEJ), but inhibits 
classical non-homologous end joining (C-NHEJ) (Figure 4). Thus PARP1 has become a 
target for anticancer interventions. G1/G0 arrest shifts error-free HR and Alt-NHEJ to error-
prone C-NHEJ, but low PARP1 impairs also BER and SSBR [32-34]. According to our new 
data, PARP1 repression by CDK4/6 inhibitors reduces PARP1-dependent 8-oxoguanine 
glycosylase (OGG1) activity, causing accumulation of single strand breaks and thereby 
increasing cell vulnerability to anticancer drugs and H2O2-induced oxidative stress [35]. The 
direct binding of OGG1 to PARP1 is stimulated by increased oxidant level, and for full activity 
OGG1 requires acetylation by EP300, which physically interacts with PARP1 and is recruited 
to some genomic loci by PARP1 [36, 37].  
PARP1 has been postulated to cooperate with transcription factor(s) that activate expression 
of genes encoding proteins contributing to DNA repair [38]. Although such a premise must be 
experimentally confirmed, PARP1 is a bona fide co-regulator of NF-κB, p53, AP-1, E2F1, and 
BRCA1, which control promoter activation, epigenetic landscape and miRNA transcription of 
DNA repairing machinery. The confirmation for likely contribution of PARP1 in regulation of 
DNA repair gene transcription comes from observations in human growth arrested 
monocytes differentiating to proliferating macrophages [39]. This process was associated 
with increased PARP1 expression, but also with transcriptional activation of XRCC1, ligase 
IIIα, OGG1 and catalytic subunit of DNA-dependent protein kinase (DNA-PKcs).  Severe DNA 
repair defects that impacted base excision repair and double-strand break repair in 
monocytes sensitized these cells to death by t-butyl hydroperoxide and irradiation with γ-
rays, while macrophages revealed almost complete resistance to these redox-challenging 
agents.  
To conclude, PARP1 provides cell with protection against oxidants at different levels: by 
activating expression of proteins setting up antioxidant defense and redox sensitive signaling 
pathways, and by fine tuning of DNA repair machinery. Therefore PARP1 expression, which 
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is defined by the proliferative status of cells, can determine cell resistance to oxidants, even 
though an adaptive response is only apparent within a narrow dose window.  
 
Acknowledgments 
AR acknowledges grants from Polish National Science Center (DEC-2013/11/D/NZ2/00033) 
and Ministry of Science and Higher Education (776/STYP/11/2016); CMS acknowledges 
funding from the European Union's Horizon 2020 research and innovation programme under 
the Marie Sklodowska-Curie grant agreement number 675132; LV acknowledges grants from 
the National Research, Development and Innovation Office (GINOP-2.3.2-15-2016-00020-
TUMORDNS, GINOP-2.3.2-15-2016-00048-STAYALIVE, OTKA K112336). 
 
 
 
 
 
 
 
 
References 
1. Molavian H.R., Kohandel M., Sivaloganathan S., High Concentrations of H2O2 Make 
Aerobic Glycolysis Energetically More Favorable for Cellular Respiration, Front 
Physiol 2016, 7:362. 
2. Lambeth J.D., Kawahara T., Diebold B., Regulation of Nox and Duox enzymatic 
activity and expression, Free Radic Biol Med 2007, 43:319-31. 
3. Liou G.Y., Storz P., Reactive oxygen species in cancer, Free Radic Res 2010, 
44:479-96. 
4. Schieber M., Chandel N.S., ROS function in redox signaling and oxidative stress, 
Curr Biol 2014, 24:453-62. 
10 
 
5. Espinosa-Diez C., Miguel V., Mennerich D., Kietzmann T., Sanchez-Perez P., 
Cadenas S., Lamas S., Antioxidant responses and cellular adjustments to oxidative 
stress, Redox Biol 2015, 6:183-97. 
6. EMBL-EBI, https://www.ebi.ac.uk/services/gene-expression, 2018  
7. Wiśnik E., Płoszaj T., Robaszkiewicz A., Downregulation of PARP1 transcription by 
promoter-associated E2F4-RBL2-HDAC1-BRM complex contributes to repression of 
pluripotency stem cell factors in human monocytes, Sci Rep 2017, 7:9483. 
8. NIH: US National Library of Medicine, https://clinicaltrials.gov/, 2018 
9. Wright R.H., Castellano G., Bonet J., Le Dily F., Font-Mateu J., Ballare C., Nacht 
A.S., Soronellas D., Oliva B., Beato M., CDK2-dependent activation of PARP-1 is 
required for hormonal gene regulation in breast cancer cells, Genes Dev 2012, 
26:1972-83. 
10. Leger K., Hopp A.K., Fey M., Hottiger M.O., ARTD1 regulates cyclin E expression 
and consequently cell-cycle re-entry and G1/S progression in T24 bladder carcinoma 
cells, Cell Cycle 2016, 15:2042-52. 
11. Wu T., Wang X.J., Tian W., Jaramillo M.C., Lau A., Zhang D.D., Poly(ADP-ribose) 
polymerase-1 modulates Nrf2-dependent transcription, Free Radic Biol Med 2014, 
67:69-80. 
12. Kansanen E., Kuosmanen S.M., Leinonen H., Levonen A.L., The Keap1-Nrf2 
pathway: Mechanisms of activation and dysregulation in cancer, Redox Biol 2013, 
1:45-9. 
13. Majmundar A.J., Wong W.J., Simon M.C., Hypoxia-inducible factors and the response 
to hypoxic stress, Mol Cell 2010, 40:294-309. 
14. Nguyen T.L., Duran R.V., Prolyl hydroxylase domain enzymes and their role in cell 
signaling and cancer metabolism, Int J Biochem Cell Biol 2016, 80:71-80. 
15. Martinez-Romero R., Martinez-Lara E., Aguilar-Quesada R., Peralta A., Oliver F.J., 
Siles E., PARP-1 modulates deferoxamine-induced HIF-1alpha accumulation through 
the regulation of nitric oxide and oxidative stress, J Cell Biochem 2008, 104:2248-60. 
11 
 
16. Oberley L.W., Mechanism of the tumor suppressive effect of MnSOD overexpression, 
Biomed Pharmacother 2005, 59:143-8. 
17. Movafagh S., Crook S., Vo K., Regulation of hypoxia-inducible factor-1a by reactive 
oxygen species: new developments in an old debate, J Cell Biochem 2015, 116:696-
703. 
18. Sies H., Oxidative stress: a concept in redox biology and medicine, Redox Biol 2015, 
4:180-3. 
19. Robaszkiewicz A., Wisnik E., Regdon Z., Chmielewska K., Virag L., PARP1 facilitates 
EP300 recruitment to the promoters of the subset of RBL2-dependent genes, Biochim 
Biophys Acta 2017,  
20. Mori S., Nada S., Kimura H., Tajima S., Takahashi Y., Kitamura A., Oneyama C., 
Okada M., The mTOR pathway controls cell proliferation by regulating the FoxO3a 
transcription factor via SGK1 kinase, PLoS One 2014, 9:e88891. 
21. Chambard J.C., Lefloch R., Pouyssegur J., Lenormand P., ERK implication in cell 
cycle regulation, Biochim Biophys Acta 2007, 1773:1299-310. 
22. Kim E.K., Choi E.J., Pathological roles of MAPK signaling pathways in human 
diseases, Biochim Biophys Acta 2010, 1802:396-405. 
23. Lee B., Cao R., Choi Y.S., Cho H.Y., Rhee A.D., Hah C.K., Hoyt K.R., Obrietan K., 
The CREB/CRE transcriptional pathway: protection against oxidative stress-mediated 
neuronal cell death, J Neurochem 2009, 108:1251-65. 
24. Glorieux C., Auquier J., Dejeans N., Sid B., Demoulin J.B., Bertrand L., Verrax J., 
Calderon P.B., Catalase expression in MCF-7 breast cancer cells is mainly controlled 
by PI3K/Akt/mTor signaling pathway, Biochem Pharmacol 2014, 89:217-23. 
25. Ismail N., Ismail M., Imam M.U., Azmi N.H., Fathy S.F., Foo J.B., Abu Bakar M.F., 
Mechanistic basis for protection of differentiated SH-SY5Y cells by oryzanol-rich 
fraction against hydrogen peroxide-induced neurotoxicity, BMC Complement Altern 
Med 2014, 14:467. 
12 
 
26. Wyrsch P., Blenn C., Bader J., Althaus F.R., Cell death and autophagy under 
oxidative stress: roles of poly(ADP-Ribose) polymerases and Ca(2+), Mol Cell Biol 
2012, 32:3541-53. 
27. Racz B., Hanto K., Tapodi A., Solti I., Kalman N., Jakus P., Kovacs K., Debreceni B., 
Gallyas F., Jr., Sumegi B., Regulation of MKP-1 expression and MAPK activation by 
PARP-1 in oxidative stress: a new mechanism for the cytoplasmic effect of PARP-1 
activation, Free Radic Biol Med 2010, 49:1978-88. 
28. Luo X., Kraus W.L., On PAR with PARP: cellular stress signaling through poly(ADP-
ribose) and PARP-1, Genes Dev 2012, 26:417-32. 
29. Hocsak E., Szabo V., Kalman N., Antus C., Cseh A., Sumegi K., Eros K., Hegedus Z., 
Gallyas F., Jr., Sumegi B., Racz B., PARP inhibition protects mitochondria and 
reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway, Free 
Radic Biol Med 2017, 108:770-784. 
30. Eustermann S., Wu W.F., Langelier M.F., Yang J.C., Easton L.E., Riccio A.A., Pascal 
J.M., Neuhaus D., Structural Basis of Detection and Signaling of DNA Single-Strand 
Breaks by Human PARP-1, Mol Cell 2015, 60:742-754. 
31. Van Meter M., Simon M., Tombline G., May A., Morello T.D., Hubbard B.P., 
Bredbenner K., Park R., Sinclair D.A., Bohr V.A., Gorbunova V., Seluanov A., JNK 
Phosphorylates SIRT6 to Stimulate DNA Double-Strand Break Repair in Response to 
Oxidative Stress by Recruiting PARP1 to DNA Breaks, Cell Rep 2016, 16:2641-2650. 
32. Chiruvella K.K., Liang Z., Wilson T.E., Repair of double-strand breaks by end joining, 
Cold Spring Harb Perspect Biol 2013, 5:a012757. 
33. Dean J.L., Mcclendon A.K., Knudsen E.S., Modification of the DNA damage response 
by therapeutic CDK4/6 inhibition, J Biol Chem 2012, 287:29075-87. 
34. Wei H., Yu X., Functions of PARylation in DNA Damage Repair Pathways, Genomics 
Proteomics Bioinformatics 2016, 14:131-139. 
35. Tempka D., Tokarz P., Chmielewska K., Kluska M., Pietrzak J., Rygielska Z., Virag L., 
Robaszkiewicz A., Downregulation of PARP1 transcription by CDK4/6 inhibitors 
13 
 
sensitizes human lung cancer cells to anticancer drug-induced death by impairing 
OGG1-dependent base excision repair, Redox Biol 2018, 15:316-326. 
36. Kang L., Zhao W., Zhang G., Wu J., Guan H., Acetylated 8-oxoguanine DNA 
glycosylase 1 and its relationship with p300 and SIRT1 in lens epithelium cells from 
age-related cataract, Exp Eye Res 2015, 135:102-8. 
37. Noren Hooten N., Kompaniez K., Barnes J., Lohani A., Evans M.K., Poly(ADP-ribose) 
polymerase 1 (PARP-1) binds to 8-oxoguanine-DNA glycosylase (OGG1), J Biol 
Chem 2011, 286:44679-90. 
38. Christmann M., Kaina B., Transcriptional regulation of human DNA repair genes 
following genotoxic stress: trigger mechanisms, inducible responses and genotoxic 
adaptation, Nucleic Acids Res 2013, 41:8403-20. 
39. Bauer M., Goldstein M., Christmann M., Becker H., Heylmann D., Kaina B., Human 
monocytes are severely impaired in base and DNA double-strand break repair that 
renders them vulnerable to oxidative stress, Proc Natl Acad Sci U S A 2011, 
108:21105-10. 
 
 
 
 
Figure 1. Cell cycle progression dictates PARP1 transcription via growth 
factors/inhibitors-G1/G0-CDK4/6-RBs axis. Cell cycle machinery is controlled by external 
signals in order to adapt cells to environmental requirements and conditions. Stimulation of 
receptor tyrosine kinases (RTKs), MYC protooncogene or estrogen receptor (ER) in 
response to peptide and non-peptide growth-promoting agents activates cyclin-dependent 
kinase 4 and 6 (CDK4/6), which associate with cyclin D1 and phosphorylate retinoblastoma 
proteins (RB1, RBL2). This modification keeps retinoblastoma proteins released from 
promoters of PARP1 and cell cycle promoting genes, thereby allowing active gene 
transcription and enabling cell transition from G1 to S phase. Upon cell growth arrest in G1 or 
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cell cycle exit to G0, CDK4/6 inhibition results in hypophosphorylation of retinoblastoma 
proteins, their binding to E2F-driven gene promoters and recruitment of chromatin 
remodelers, which are capable of inactivating gene expression by removing transcription-
promoting indicators and/or inserting transcription-inhibiting histone modification(s). It leads 
to an increase in nucleosome density and chromatin condensation. Notably, composition of 
the repressive complex varies between cells arrested in G1 and in G0. Limiting PARP1 
expression in G0 is achieved solely by histone deacetylase 1 (HDAC1) for histone 
deacetylation, while in G1 HDAC1 additionally requires PRC2 (polycomb repressor complex 
2) activity and trimethylation of H3K27 by enhancer of zeste homolog 2 (EZH2) to repress 
PARP1 transcription. Cell cycle arrest in G2 does not affect the mRNA and protein levels of 
PARP1.  
Figure 2. PARP1 contributes to antioxidant cell defense by enhancing transcription of 
enzymatic scavengers of electrophiles and secondary metabolites. Under normal 
oxygen conditions, PARP1 determines intracellular redox homeostasis by intensifying 
nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2)-dependent transcription of 
enzymatic redox-balancing enzymes (NAD(P)H quinone oxidoreductase 1, NQO1; heme 
oxygenase-1, HO-1; aldo-keto reductase family 1, member C1, AKR1C1; superoxide 
dismutase 1, SOD1), as well as phase II detoxifying enzymes (glutathione S-transferase, 
GST; UDP-glucuronosyltransferase, UGT; catalytic and modifier subunits of glutamate 
cysteine ligase, GCLC and GCLM respectively) and drug transporters (multidrug resistance-
associated proteins, MRPs). In the absence of PARP1, transcription of the above-mentioned 
genes is restricted as NRF2 moderately associates with small MAF proteins (in this case with 
MAFG) and the antioxidant response element (ARE), which is localized within the promoter 
of NRF2 target genes. When abundant, PARP1 enhances the interaction among NRF2, 
MAFG and ARE, thereby acting as a co-activator of NRF2-dependent gene transcription.  
PARP1 also functions actively in cell adaptive responses to match O2 supply under hypoxia 
by supporting hypoxia-inducible factor 1-alpha (HIF1α) at different signaling levels. This 
protein, together with PARP1, acts as a key modulator of the transcription response in cells 
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that experience a low O2 level. Under normal oxygen condition, factor inhibiting HIF1α (FIH1; 
asparaginyl hydroxylase) and propyl hydroxylase domain-containing enzymes (PHDs) 
hydroxylate HIF1α, thereby preventing transcription factor interaction with EP300/CBP 
coactivators and marking HIF1α for proteasomal degradation by E3 ubiquitin ligase, the von 
Hippel-Lindau (pVHL) complex. Low O2 concentration inhibits hydroxylases and stabilizes 
HIF1α. PARP1 forms complex and co-activates HIF1α in a PARP1 enzymatic activity-
dependent manner, therefore enabling expression of genes controlled by hypoxia response 
element (HRE)-positive promoters. This group comprises antioxidant defense enzymes such 
as heme oxygenase-1 (HO-1), glutathione peroxidase 8 (GPX8), ER oxidoreductin 1 (ERO1) 
and glucose transporter 1 (GLUT1), the activity of which helps to maintain glutathione 
homeostasis.  
Figure 3. PARP1 contributes to regulation of redox-related signaling pathways. PARP1 
regulates both positively and negatively transcription of numerous enzymes involved in the 
transmitting signals to and from oxidant-releasing intracellular systems or extracellular 
sources. Expression of MAP2K6 and ERK1 are, like PARP1, controlled by cell cycle 
progression and RB-based repressive complexes. In proliferating cells, PARP1 is 
indispensable for their transcription, because it mediates EP300 recruitment to their 
promoters. Although AKT and ERK2 are not directly repressed by RBs, PARP1 maintains 
their expression. All these kinases were shown to protect proliferating cells facing mild or 
physiological increases in the electrophile abundance from death. In the AKT pathway, PI3 
acts as a redox sensor and after activation phosphorylates AKT, which in turn activates 
mTOR kinase. This enzyme stimulates cell proliferation via the SGK1-FOXO3 pathway, 
which represses transcription of CDK inhibitors. Moreover, mTOR phosphorylates and 
inactivates BAD, thus blocking the release of cytochrome c from mitochondria. AKT 
contributes to H2O2 accumulation by stimulating oxidative metabolism and FOXO-dependent 
repression of catalase. Growth factors and oxidants switch on ERK signaling via RAS, which, 
depending on the isoform expressed in a particular cell type, shifts up or down the 
intracellular level of oxidants. Ha-RAS isoform promotes O2
•- accumulation by activating 
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NADPH oxidase, while the Ki-RAS pathway upregulates transcription of SOD2. There are 
numerous ERK targets, which implicate this enzyme in cell proliferation: carbamoyl 
phosphate synthetase (CPS II, source of pyrimidine nucleotides), MSK1/2 (chromatin 
remodeling and induction of cell cycle-related gene transcription), RNA polymerase I 
(transcription of the ribosomal RNA genes), CDK inhibitors or MYC (transcription of cyclin 
D1). ERK protects cells from death by repressing pro-apoptotic BIM and stabilizing anti-
apoptotic MCL-1 protein. PARP1-MAP2K6 functional cross-talk at the genomic level is not 
limited to upregulation of kinase transcription. MAP2K6 links PARP1 with transcription of 
anti-apoptotic genes indirectly by starting the phosphorylation cascade MAP2K6-p38-
MSK1/2-CREB. The last component of this axis controls transcription of HO-1 and PGC-1α; 
the latter promotes mitochondrial biogenesis. Furthermore, PARP1 regulates activity of 
MAPKs independently of their promoters by regulating transcription of JNK, ER1/2 and the 
p38 inhibitor MKP1. Downregulation of MKP1 expression by PARP1 blocks 
dephosphorylation of tyrosine and threonine residues of MAPKs, which undergo activation 
upon acute cell exposure to H2O2.  
Figure 4. PARP1 regulates repair of oxidative DNA damages. The cell decision on 
involvement of particular repair system depends on the type of DNA damage and is strongly 
related to cell cycle progression. For double strand breaks, the cell is equipped with three 
repair systems: homologous recombination (HR), classical non-homologous end joining (C-
NHEJ) or alternative non-homologous end joining (Alt-NHEJ). Proliferating cells, with high 
PARP1 levels, make use mainly of two mechanisms: HR and/or Alt-NHEJ, which assure 
accurate and error-free repair of double strand breaks since they use a replicated DNA 
template to reconstruct the missing fragment with high fidelity. These two pathways rely on 
the recognition of detrimental lesions by PARP1, which recruits other proteins to the affected 
sites: first MRN complex (consisting of MRE11, Rad50, Nbs1), an initiator of repair, then 
MRE11 determines the composition of proteins for each repair mechanism (HR or NHEJ).  
The low C-NHEJ involvement in repair is achieved by high expression of PARP1, an inhibitor 
of DNA-dependent protein kinases (DNA-PKcs), which is crucial for C-NHEJ progression. In 
17 
 
G1/G0 arrested cells (deficient in HR and Alt-NHEJ), low expression of PARP1 allows 
recruitment of the Ku70/80 heterodimer to double strand breaks and sites of DNA-PKcs 
activation. Repair machinery such as nuclease Artemis, DNA ligase IV and XRCC4 further 
process the damaged DNA and directly ligate DNA ends, leading to the irreversible loss of 
genetic material.  
Base excision repair (BER) is a substantial pathway to repair oxidized bases. The damaged 
base is recognized and removed by OGG1 glycosylase, which requires PARP1 for proper 
and efficient functioning. AP endonuclease (APE1) is binds to apurynic sites and produces 
single-strand breaks (SSBs), which again involve PARP1 in the BER machinery at a later 
repair step. DNA nick-induced poly-ADP-ribosylation facilitates PARP1 interaction with 
DNAPδ/ε and PCNA, which further govern repair machinery. Single strand breaks resulting 
from direct oxidant action also need PARP1 activity to be repaired. Poly-ADP-ribose 
polymers recruit XRCC1, then the remaining SSBR machinery comprising DNA polymerase 
(DNAP) and DNA ligase III, which also can be PARylated by PARP1. PARP1 deficiency in 
growth-arrested cells substantially impairs both pathways. Of note, inhibition of OGG1 in 
combination with G1-blockade leads to further accumulation of single strand breaks. 
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Highlights 
· Cell proliferation determines PARP1 transcription and production of electrophiles  
· PARP1 contributes to cell protection against electrophiles 
· PARP1 controls transcription of redox-sensitive kinases, antioxidants and detoxifying 
enzymes 
· DNA repair machinery requires PARP1 to maintain genome integrity 
· G1 and G0 arrest vulnerable cells during mild oxidative stress 
 
B
R
M
 
H
D
A
C
1
 
C
y
c
li
n
 D
1
 
D
1
D
1
D
1
D
1
D
1
D
1
D
1 C
D
K
4
/6
 
G
0
 
0
S
 
P
A
R
P
1
 p
ro
m
o
te
r 
P
A
R
P
1
 p
ro
m
o
te
r 
P
A
R
P
1
 p
ro
m
o
te
r 
IN
K
4
s
 
C
IP
/K
IP
s
 
S
e
n
e
s
c
e
n
c
e
 
D
if
fe
re
n
ti
a
ti
o
n
 
S
tr
e
s
s
 r
e
s
p
o
n
s
e
 
C
D
K
4
/6
 i
n
h
ib
it
o
rs
 
C
h
e
m
ic
a
l 
a
g
e
n
ts
 (
e
.g
. 
m
im
o
s
in
e
) 
G
ro
w
th
 f
a
c
to
r 
w
it
h
d
ra
w
a
l 
G
S
K
3
β
 
R
B
L
2
 
S
P
1
 
E
2
F
4
 
H
3
K
2
7
m
e
3
 
A
c
B
R
G
1
 
B
R
M
 
H
D
A
C
1
 
E
Z
H
2
 
S
P
1
 
R
B
1
 
E
2
F
1
 
R
B
L
2
 
R
B
1
 
O
F
F
 
O
F
F
 
O
N
 
M
Y
C
 
R
T
K
s
 E
R
 
P
h
o
s
p
h
o
 
H
o
rm
o
n
e
s
 
C
y
to
k
in
e
s
 
G
ro
w
th
 f
a
c
to
rs
 
 
S
P
1
 
P
O
L
R
2
A
 
F
ig
u
re
 1
 
P
A
R
P
1
 
P
A
R
P
1
 
H
R
E
 
P
H
D
s F
IH
1
 
O
F
F
 
H
IF
1
α
 p
V
H
L
 
E
2
 
C
B
P
 
PPPP
E
P
3
0
0
 
H
R
E
 
E
P
A
R
P
1
 
•
G
P
X
8
 
•
H
O
-1
 
•
E
R
O
1
 
•
G
L
U
T
1
 
O
N
 
F
IH
1
 
P
H
D
s
 
H
Y
P
O
X
IA
 
N
O
R
M
O
X
IA
 
A
R
E
 
M
A
F
G
 
O
N
 
•
N
Q
O
1
 
•
H
O
-1
 
•
A
K
R
1
C
1
 
•
S
O
D
1
 
•
G
S
T
 
•
U
G
T
 
•
G
C
L
C
/G
C
L
M
 
•
M
R
P
s
 
G
N
R
F
2
 
P
A
R
P
1
 
P
A
R
P
1
 
H
IG
H
 P
A
R
P
1
 
M
A
F
G
 
N
R
F
2
 
O
N
L
O
W
 P
A
R
P
1
 
A
R
E
 
P
A
R
P
1
 
O
H
 
A
D
P
-r
ib
o
s
e
 
H
IF
1
α
 
F
ig
u
re
 2
G
e
n
e
s
 
P
 
C
Y
T
O
S
O
L
 
P
I3
K
 
m
T
O
R
 
 C
e
ll
 p
ro
li
fe
ra
ti
o
n
 
P
 
PPP
P
3
8
 
M
S
K
1
/2
 
P
 
P
E
R
K
1
/2
 
R
A
S
 
N
U
C
L
E
U
S
 
S
G
K
1
 
M
C
L
1
 
A
K
T
 
P
 
P
 
P
M
A
P
2
K
6
T
F
 
P
A
R
P
 
iN
O
S
 
N
G
F
R
 
IK
B
K
B
 
A
K
T
 
E
R
K
1
/2
 
M
A
P
2
K
6
 
M
P
K
1
M
Y
D
8
8
 
R
A
C
1
 
P
IK
3
R
1
 
•
C
D
K
 i
n
h
ib
it
o
rs
 
•
C
y
c
li
n
s
 
•
C
D
K
s
 
•
C
P
S
 I
I 
•
M
S
K
1
/2
 
•
P
O
L
1
  
C
e
ll
  
a
p
o
p
to
s
is
 
C
R
E
B
 
PP
B
A
D
 
B
IM
 
•
C
A
T
 
•
M
n
S
O
D
 
•
N
A
D
P
H
o
x
 
R
e
d
o
x
  
h
o
m
e
o
s
ta
s
is
 
F
ig
u
re
 3
 
G
e
n
e
s
 
P
R
O
L
IF
E
R
A
T
IN
G
 C
E
L
L
S
 
G
1
/G
0
 A
R
R
E
S
T
E
D
 C
E
L
L
S
 
D
S
B
R
 
C
-N
H
E
J
 
H
R
 
A
lt
-N
H
E
J
 
B
E
R
 
A
rt
e
m
is
 
A
rt
e
m
is
 
B
E
R
 
S
S
B
R
 
X
R
C
C
1
 
L
ig
 3
 
P
o
lß
 
P
A
R
P
1
 
A
P
E
1
 
O
G
G
1
 
D
N
A
-P
K
c
s
 
C
-N
H
E
J
 
P
A
R
P
1
 
P
A
R
P
1
 
M
R
N
 
M
R
N
 
B
R
C
A
1
 
H
R
 
P
A
R
P
1
 
P
o
lδ
/ε 
P
o
P
o
P
A
R
P
1
 
P
C
N
A
 
X
R
C
C
1
 
X
R
P
A
R
P
1
 
A
lt
-N
H
E
J
 
S
h
o
rt
 r
e
g
io
n
 o
f 
h
o
m
o
lo
g
y
 
P
A
R
P
1
 
P
A
R
P
1
 
M
R
N
 
M
R
N
 
D
N
A
-P
K
c
s
 
D
N
A
-P
K
c
s
 
L
ig
 4
 
L
ig
 1
 
F
e
n
1
 
P
C
N
A
 
O
G
G
1
 
c
sK
u
 
A
r
A
r
D
N
D
N
K
u
 
D
S
B
R
 
D
S
B
R
D
S
B
R
F
ig
u
re
 4
 
